Cargando…
Efficacy and safety of cannabidivarin treatment of epilepsy in girls with Rett syndrome: A phase 1 clinical trial
OBJECTIVE: Rett syndrome (RTT), commonly caused by methyl‐CpG‐binding protein 2 (MECP2) pathogenic variants, has many comorbidities. Fifty to ninety percent of children with RTT have epilepsy, which is often drug‐resistant. Cannabidivarin (CBDV), a non‐hallucinogenic phytocannabinoid, has shown bene...
Autores principales: | Hurley, Ellen N., Ellaway, Carolyn J., Johnson, Alexandra M., Truong, Linda, Gordon, Rebecca, Galettis, Peter, Martin, Jennifer H., Lawson, John A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9544893/ https://www.ncbi.nlm.nih.gov/pubmed/35364618 http://dx.doi.org/10.1111/epi.17247 |
Ejemplares similares
-
Cannabidivarin (CBDV) suppresses pentylenetetrazole (PTZ)-induced increases in epilepsy-related gene expression
por: Amada, Naoki, et al.
Publicado: (2013) -
Cannabis in epilepsy: From clinical practice to basic research focusing on the possible role of cannabidivarin
por: Morano, Alessandra, et al.
Publicado: (2016) -
A Phase 2 Randomized Controlled Trial of the Efficacy and Safety of Cannabidivarin as Add-on Therapy in Participants with Inadequately Controlled Focal Seizures
por: Brodie, Martin J., et al.
Publicado: (2021) -
The Quality of Life in Girls with Rett Syndrome
por: Parisi, Lucia, et al.
Publicado: (2016) -
Sleep Respiratory Disturbances in Girls with Rett Syndrome
por: Zhang, Xinyan, et al.
Publicado: (2022)